Table 2. Parasitemia peak of T. cruzi-infected mice treated or not with DB289 and DB766 associated or not with Benznidazole (Bz).

Experimental group	Therapy route	Parasitemia peak (×104 par/mL) and (% parasite reduction)
Untreated1	-	150.98±27.3
Bz 50 mg/kg1	p.o.	9.6±10.2 (93%)*
DB766 50 mg/kg1	ip	0.9±1.1 (99.4%)*
DB766 50 mg/kg+Bz 50 mg/kg1	ip+p.o.	0.0±0.0 (100%)* and **
Untreated2	-	95±12.8
Bz 50 mg/kg2	p.o.	10.5±14.4 (89%)*
DB766 50 mg/kg2	p.o.	78±88 (17%)
DB766 50 mg/kg+Bz 50 mg/kg2	p.o.+p.o.	43.6±31 (54%)*
DB766 50 mg/kg2	ip	4±3 (96%)*
DB766 50 mg/kg+Bz 50 mg/kg2	ip+p.o.	0.5±1 (99.5%)* and **
DB289 25 mg/kg2	p.o.	26.4±14.4 (72%)*
DB289 25 mg/kg+Bz 50 mg/kg2	p.o.+p.o.	1.2±1 (99%)* and **

1 and 2 = two independent representative studies.

*The single asterisk indicates statistically significant differences (p≤0.05) between untreated and treated groups.

**The double asterisk indicates statistically significant differences (p≤0.05) between the animal group that received the compound alone and in combination with Bz.